<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="http://www.rivervest.com/wp-content/plugins/google-sitemap-generator/sitemap.xsl"?><!-- generator="wordpress/2.8.6" --><!-- sitemap-generator-url="http://www.arnebrachhold.de" sitemap-generator-version="3.1.2" --><!-- generated-on="February 1, 2012 4:57 pm" --><!-- Debug: Total comment count: 0 --><urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">	<url>
		<loc>http://www.rivervest.com/</loc>
		<lastmod>2012-01-10T17:07:12+00:00</lastmod>
		<changefreq>daily</changefreq>
		<priority>1.0</priority>
	</url>
<!-- Debug: Start Postings -->	<url>
		<loc>http://www.rivervest.com/case-studies/case-study-2/</loc>
		<lastmod>2012-02-01T16:56:27+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/team/john-mckearn/</loc>
		<lastmod>2012-02-01T16:48:45+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/team-2/john-mckearn-phd/</loc>
		<lastmod>2012-02-01T16:45:26+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/case-studies/case-study-3/</loc>
		<lastmod>2012-02-01T16:43:47+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/home/home-page-case-study-3/</loc>
		<lastmod>2012-02-01T16:15:59+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/portfolio/</loc>
		<lastmod>2012-02-01T16:13:26+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/portfolio-2/</loc>
		<lastmod>2012-02-01T16:09:14+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/case-studies/case-study-1/</loc>
		<lastmod>2012-02-01T15:46:35+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/case-studies/</loc>
		<lastmod>2012-02-01T15:34:40+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/home/home-page-case-study-1/</loc>
		<lastmod>2012-02-01T15:33:28+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/team/karen-spilizewski/</loc>
		<lastmod>2012-02-01T15:16:37+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/team-2/karen-spilizewski/</loc>
		<lastmod>2012-02-01T15:15:02+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/team/niall-odonnell/</loc>
		<lastmod>2012-02-01T15:04:05+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/team-2/niall-odonnell-phd/</loc>
		<lastmod>2012-02-01T15:01:46+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/team/thomas-c-melzer/</loc>
		<lastmod>2012-02-01T14:56:55+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/team-2/thomas-c-melzer/</loc>
		<lastmod>2012-02-01T14:40:19+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/team/jay-schmelter/</loc>
		<lastmod>2012-02-01T14:30:29+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/team-2/jay-w-schmelter/</loc>
		<lastmod>2012-02-01T14:26:41+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 2708: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/bard-acquires-lutonix-inc/</loc>
		<lastmod>2012-01-10T17:07:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2698: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/pfizer-to-acquire-excaliard-pharmaceuticals/</loc>
		<lastmod>2011-11-22T13:50:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2694: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/3000-patient-meta-analysis-reinforces-importance-of-platelet-reactivity-testing-to-aid-in-risk-assessment/</loc>
		<lastmod>2011-11-08T17:56:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2665: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/new-data-underscores-importance-of-platelet-reactivity-testing-to-aid-in-risk-assessment/</loc>
		<lastmod>2011-10-11T16:09:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2679: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/jumpstart-and-rivervest-invest-in-medical-device-firm-company-relocates-to-cleveland-from-boston/</loc>
		<lastmod>2011-10-11T16:08:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2675: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/otonomy-presents-positive-new-findings-from-phase-1b-study-of-oto-104-in-meniere%e2%80%99s-disease-at-international-conference/</loc>
		<lastmod>2011-09-29T16:51:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2671: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/varian-medical-systems-signs-agreement-to-acquire-calypso-medical-technologies-acquisition-adds-products-for-tracking-tumor-motion-during-radiosurgery-and-radiotherapy/</loc>
		<lastmod>2011-09-28T13:38:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2668: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/platelet-reactivity-testing-included-in-2011-guideline-recommendations-from-european-society-of-cardiology/</loc>
		<lastmod>2011-09-22T13:04:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2653: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/university-hospitals-and-centerre-healthcare-announce-joint-venture-to-open-comprehensive-inpatient-rehabilitation-hospital/</loc>
		<lastmod>2011-08-29T14:14:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2655: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/centerre-healthcare-corporation-and-mercy-health-center-announce-new-rehab-hospital/</loc>
		<lastmod>2011-08-29T14:09:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2649: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/idev-technologies-announces-completion-of-superb-clinical-trial-enrollment/</loc>
		<lastmod>2011-08-03T15:35:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2643: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/texas-rehabilitation-hospital-brings-inpatient-traumatic-brain-injury-spinal-cord-rehabilitation-to-tarrant-county/</loc>
		<lastmod>2011-07-28T12:53:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2639: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/idev-technologies-launches-lower-profile-supera-veritas%c2%ae-stent-delivery-system/</loc>
		<lastmod>2011-07-28T12:31:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2635: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/first-patient-enrolled-in-lutonix-drug-coated-balloon-pivotal-trial/</loc>
		<lastmod>2011-07-26T13:48:09+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/team/</loc>
		<lastmod>2011-07-18T19:18:23+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/team-2/</loc>
		<lastmod>2011-07-18T19:14:54+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 2617: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/medtronic-to-acquire-salient-surgical-technologies-inc/</loc>
		<lastmod>2011-07-13T13:37:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2613: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/new-ce-marked-prognostic-claim-for-the-verifynow-p2y12-test/</loc>
		<lastmod>2011-05-20T20:00:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2609: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-signs-national-distribution-agreement-with-cardinal-health/</loc>
		<lastmod>2011-05-11T17:59:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2600: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/john-mckearn-ph-d-promoted-to-managing-director-of-rivervest-venture-partners/</loc>
		<lastmod>2011-05-03T13:25:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/case-studies/venturing-into-the-ear-frontier/</loc>
		<lastmod>2011-05-03T02:16:54+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/home/home-page-case-study-4/</loc>
		<lastmod>2011-05-03T02:15:37+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 2582: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/2011-accfaha-guidelines-incorporate-new-recommendation-for-platelet-reactivity-testing/</loc>
		<lastmod>2011-04-28T19:11:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2578: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/otonomy-announces-positive-results-from-phase-1b-study-of-oto-104-in-meniere%e2%80%99s-disease/</loc>
		<lastmod>2011-04-28T18:58:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2564: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/mpex-pharmaceuticals-inc-to-be-acquired-by-axcan/</loc>
		<lastmod>2011-04-15T15:25:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/team/andrew-b-craig-iii/</loc>
		<lastmod>2011-04-04T14:07:52+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/team-2/andy/</loc>
		<lastmod>2011-04-04T14:06:02+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 2550: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/2011-surgical-guidelines-recommend-point-of-care-platelet-reactivity-testing-prior-to-surgery/</loc>
		<lastmod>2011-03-09T20:34:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2548: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-signs-development-supply-agreement-with-portola-pharmaceuticals-inc/</loc>
		<lastmod>2011-03-07T15:06:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2544: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/ligand-acquires-cydex-pharmaceuticals/</loc>
		<lastmod>2011-01-27T15:50:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2539: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/mpex-initiates-phase-3-clinical-trial-program-with-aeroquintm-for-the-treatment-of-chronic-bacterial-infections-in-cystic-fibrosis-patients/</loc>
		<lastmod>2011-01-24T19:53:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2535: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/excaliard-announces-positive-results-from-three-phase-2-clinical-trials-for-exc-001-showing-significant-improvement-in-both-hypertrophic-and-fine-line-scarring/</loc>
		<lastmod>2011-01-10T21:42:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/contact-us/rivervest-newsletter/</loc>
		<lastmod>2011-01-04T19:12:49+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/contact-us/newsletter-sign-up/</loc>
		<lastmod>2011-01-04T18:36:42+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 2508: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/icad-to-acquire-xoft-inc/</loc>
		<lastmod>2010-12-17T20:25:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2499: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-closes-2010-with-positive-outlook/</loc>
		<lastmod>2010-12-10T17:21:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2494: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/otonomy-appoints-david-a-weber-ph-d-chief-executive-officer/</loc>
		<lastmod>2010-12-09T13:24:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/about-us/</loc>
		<lastmod>2010-11-30T14:33:48+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/about/</loc>
		<lastmod>2010-11-30T14:33:13+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 2476: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/gravitas-trial-shows-that-a-uniform-treatment-strategy-of-doubling-the-standard-dose-of-plavix-does-not-improve-outcomes-post-pci/</loc>
		<lastmod>2010-11-16T16:27:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2471: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/idev-technologies-announces-fda-510k-clearance-for-supera-veritas%e2%84%a2/</loc>
		<lastmod>2010-11-03T15:57:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2468: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/macrogenics-enters-global-research-collaboration-and-license-agreement-with-pfizer/</loc>
		<lastmod>2010-10-28T18:37:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2461: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/boehringer-ingelheim-and-macrogenics-announce-global-alliance-to-discover-develop-and-commercialize-dart%e2%84%a2-based-antibody-therapeutics/</loc>
		<lastmod>2010-10-26T14:38:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2456: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/cydex-pharmaceuticals-obtains-full-development-and-commercialization-rights-to-novel-captisol-enabled%c2%ae-intravenous-formulation-of-clopidogrel/</loc>
		<lastmod>2010-10-26T14:17:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2449: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/excaliard-pharmaceuticals-appoints-thomas-wiggans-to-chairman-of-the-board/</loc>
		<lastmod>2010-10-18T19:30:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2445: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/idev-technologies-completes-46-million-preferred-stock-financing-with-piper-jaffray-and-additional-strategic-investor/</loc>
		<lastmod>2010-10-14T16:19:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2442: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/calypso-medical-receives-fda-510k-clearance-for-dynamic-edge-gating-technology/</loc>
		<lastmod>2010-10-14T16:14:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2439: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/tryton-completes-20-million-financing-to-accelerate-u-s-pivotal-trial/</loc>
		<lastmod>2010-09-16T16:39:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2436: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-increases-capital-raise-completes-final-close-in-24-million-capital-financing/</loc>
		<lastmod>2010-09-01T15:33:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2424: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/otonomy-closes-38-5-million-series-b-financing/</loc>
		<lastmod>2010-08-31T13:42:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2421: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/idev-technologies-enters-into-an-exclusive-distribution-agreement-with-trireme-medical/</loc>
		<lastmod>2010-07-21T18:28:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2415: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-inc-daiichi-sankyo-inc-and-eli-lilly-and-company-launch-strategic-u-s-collaboration/</loc>
		<lastmod>2010-07-13T19:16:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2411: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/gilead-sciences-to-acquire-cgi-pharmaceuticals-for-up-to-120-million/</loc>
		<lastmod>2010-06-25T15:07:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2407: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/idev-technologies-announces-european-launch-of-supera-veritas%e2%84%a2-stent-delivery-system/</loc>
		<lastmod>2010-05-26T14:06:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2403: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/idev-technologies-names-veteran-healthcare-executive-dennis-donohoe-m-d-chief-medical-officer/</loc>
		<lastmod>2010-05-24T18:39:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2400: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/mpex-pharmaceuticals-presents-positive-phase-2-clinical-trial-results-of-aeroquin%e2%84%a2-mp-376-treatment-in-cystic-fibrosis-patients/</loc>
		<lastmod>2010-05-18T13:38:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2395: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/research-published-in-the-new-england-journal-of-medicine-highlights-potential-benefits-of-cameron-health%e2%80%99s-s-icd-system-the-first-minimally-invasive-implantable-defibrillator-for-the-treatme/</loc>
		<lastmod>2010-05-18T13:30:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2392: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/texas-health-fort-worth-and-centerre-healthcare-corporation-to-open-inpatient-rehabilitation-facility/</loc>
		<lastmod>2010-04-30T20:00:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2385: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/cydex-pharmaceuticals-initiates-dosing-for-phase-2a-oncology-drug-trial/</loc>
		<lastmod>2010-04-30T19:31:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2378: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/inadequate-response-to-clopidogrel-leads-to-higher-incidence-of-major-adverse-cardiac-events-in-patients-who-have-undergone-pci/</loc>
		<lastmod>2010-04-06T18:58:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2372: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-inc-announces-completion-of-gravitas-trial-enrollment/</loc>
		<lastmod>2010-04-06T18:39:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2365: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/rivervest-venture-partners-promotes-niall-o%e2%80%99donnell-ph-d-to-principal/</loc>
		<lastmod>2010-04-01T13:04:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2362: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/cameron-health-inc-appoints-kevin-hykes-president-and-chief-executive-officer/</loc>
		<lastmod>2010-03-24T20:47:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2352: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/urology-study-shows-reduced-side-effects-from-radiation-for-prostate-cancer-with-calypso-medical%e2%80%99s-tumor-tracking-technology/</loc>
		<lastmod>2010-03-09T17:15:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2345: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/excaliard-initiates-phase-2-trials-in-u-s-for-its-skin-scarring-drug-exc-001/</loc>
		<lastmod>2010-01-25T16:58:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2340: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/cydex-pharmaceuticals-receives-a-key-u-s-patent-for-composition-of-matter-and-process-of-manufacturing-high-purity-captisol%c2%ae/</loc>
		<lastmod>2010-01-25T16:47:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2336: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-closes-2009-with-positive-outlook/</loc>
		<lastmod>2010-01-05T15:23:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2332: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/tryton-announces-registry-evaluating-tryton-stent-system-for-left-main-disease-and-celebrates-500th-implant/</loc>
		<lastmod>2010-01-05T15:14:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2329: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/idev-technologies-names-christopher-m-owens-president-chief-executive-officer/</loc>
		<lastmod>2009-11-19T15:49:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2326: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/cydex-pharmaceuticals-adds-industry-veteran-to-accelerate-product-commercialization-initiatives/</loc>
		<lastmod>2009-10-26T15:30:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2319: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/lutonix-inc-announces-first-patient-enrollments-in-three-separate-clinical-trials/</loc>
		<lastmod>2009-10-26T14:48:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2312: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/xoft-expands-cancer-treatment-platform-with-launch-of-skin-cancer-electronic-brachytherapy-trial-at-aapm-meeting/</loc>
		<lastmod>2009-10-26T14:19:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2308: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/luminous-medical-inc-secures-exclusive-rights-to-glucose-sensor-for-its-automated-glucose-monitor/</loc>
		<lastmod>2009-10-26T13:57:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2305: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-announces-16-5m-in-new-capital-financing/</loc>
		<lastmod>2009-10-06T12:55:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2250: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/fda-accepts-cydex-pharmaceuticals%e2%80%99-ind-application-for-oncology-drug/</loc>
		<lastmod>2009-10-02T15:06:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2298: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/calypso-medical-closes-50-million-venture-financing-round/</loc>
		<lastmod>2009-10-02T15:06:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2292: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-inc-announces-endotech-spa-as-exclusive-distributor-for-the-verifynow-system-in-italy/</loc>
		<lastmod>2009-09-17T19:54:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2286: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/mpex-pharmaceuticals-announces-positive-phase-2b-clinical-trial-results-with-aeroquin%c2%ae-mp-376-treatment-in-cystic-fibrosis-patients/</loc>
		<lastmod>2009-09-17T14:16:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2281: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/paulo-f-costa-joins-macrogenics-board-of-directors/</loc>
		<lastmod>2009-08-04T16:03:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2278: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/macrogenics-and-lilly-achieve-targeted-patient-enrollment-in-protege-a-global-phase-23-clinical-trial-of-teplizumab-in-type-1-diabetes/</loc>
		<lastmod>2009-08-04T15:56:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2273: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics%e2%80%99-verifynow%c2%ae-p2y12-test-provides-physicians-with-information-to-assess-a-patient%e2%80%99s-response-to-newly-approved-prasugrel-effient%c2%ae/</loc>
		<lastmod>2009-08-03T20:33:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2269: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-inc-announces-gravitas-trial-50-percent-enrolled/</loc>
		<lastmod>2009-08-03T20:16:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2254: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/published-studies-highlight-calypso-medicals-role-in-enabling-real-time-adaptive-radiation-delivery-to-moving-tumors/</loc>
		<lastmod>2009-08-03T19:49:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2243: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/gregory-j-tibbitts-appointed-chief-financial-officer-at-accumetrics-inc/</loc>
		<lastmod>2009-05-19T15:58:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2240: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/calypso%c2%ae-medicals-customers-obtain-reimbursement-for-intrafraction-tracking-and-beacon%c2%ae-transponders/</loc>
		<lastmod>2009-05-19T15:48:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2231: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/fda-clears-new-skin-and-surface-treatment-applicator-for-use-with-xofts-axxent%c2%ae-electronic-brachytherapy-ebx-system/</loc>
		<lastmod>2009-05-19T15:30:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2227: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-inc-announces-united-kingdom-distribution-agreement-with-elitech-uk-limited/</loc>
		<lastmod>2009-05-19T14:21:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2215: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/salient-surgical-technologies-launches-new-advanced-energy-device-designed-to-improve-patient-outcomes-in-spine-surgery/</loc>
		<lastmod>2009-05-18T20:28:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2208: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/us-food-and-drug-administration-clears-way-for-multicenter-clinical-trial-of-idev-technologies-supera-peripheral-stent/</loc>
		<lastmod>2009-05-18T19:53:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2198: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/cydex-pharmaceuticals-presents-phase-2-clinical-trial-results-for-captisol-enabled%c2%ae-budesonideazelastine-combination-solution-nasal-spray-at-american-academy-of-allergy-asthma-and-immunology-aa/</loc>
		<lastmod>2009-05-18T19:10:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2163: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/fda-clears-new-skin-and-surface-treatment-applicator-for-use-with-xofts-axxent%c2%ae-electronic-brachytherapy-cbx-system/</loc>
		<lastmod>2009-03-17T16:53:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2061: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/duke-university-medical-center-optimizes-radiation-treatment-targeting-and-efficiency-with-calypso%c2%ae-4d-localization-system%e2%84%a2/</loc>
		<lastmod>2009-02-25T21:34:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2116: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/salient-surgical-technologies-elects-bobby-i-griffin-to-board-of-directors/</loc>
		<lastmod>2009-02-25T21:32:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2139: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/cydex-pharmaceuticals-announces-captisol%c2%ae-technology-used-in-recently-approved-cosolvent-free-formulation-of-amiodarone-iv/</loc>
		<lastmod>2009-02-25T20:41:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 2126: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/cydex-pharmaceuticals-receives-orphan-drug-designation-for-melphalan/</loc>
		<lastmod>2009-02-25T19:04:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/team/william-a-peck/</loc>
		<lastmod>2009-02-25T16:27:47+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/team-2/william-a-peck/</loc>
		<lastmod>2009-02-25T16:27:22+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/team/nancy-j-hutson/</loc>
		<lastmod>2009-02-25T16:21:50+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/team-2/nancy-j-hutson/</loc>
		<lastmod>2009-02-25T16:21:01+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/team-2/joseph-m-davie/</loc>
		<lastmod>2009-02-25T16:19:54+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/team/joseph-m-davie/</loc>
		<lastmod>2009-02-25T16:18:59+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/team-2/michael-berman/</loc>
		<lastmod>2009-02-25T16:16:07+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/team/michael-berman/</loc>
		<lastmod>2009-02-25T16:15:17+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/team/floyd-e-bloom/</loc>
		<lastmod>2009-02-25T16:11:24+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/team-2/floyd-e-bloom/</loc>
		<lastmod>2009-02-25T16:08:36+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 1811: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/mpex-pharmaceuticals-announces-series-d-financing-of-up-to-40-million/</loc>
		<lastmod>2009-02-24T21:19:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1746: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/lutonix-inc-announces-20-million-series-b-financing/</loc>
		<lastmod>2009-02-24T21:17:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1769: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/tryton-medical-announces-two-key-hires-and-relocation-to-research-triangle-park-nc/</loc>
		<lastmod>2009-01-08T17:52:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/contact-us/</loc>
		<lastmod>2008-10-18T19:33:15+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 86: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/rivervest-venture-partners%e2%84%a2-closes-on-fund-i-former-nationsbank-chairman-andy-craig-and-former-head-of-federal-reserve-bank-of-st-louis-tom-melzer-are-among-founders/</loc>
		<lastmod>2008-10-18T19:26:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 82: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/rivervest-venture-partners%c2%ae-names-new-associate-and-scientific-advisor/</loc>
		<lastmod>2008-10-18T19:25:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 68: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/rivervest-venture-partners-names-dennis-wahr-md-managing-director/</loc>
		<lastmod>2008-10-18T19:24:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 64: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/rivervest-venture-partners-names-gordon-foulkes-phd-venture-partner-promotes-scott-naisbitt-md-phd-to-principal/</loc>
		<lastmod>2008-10-18T19:23:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 137: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/lilly-and-macrogenics-announce-licensing-and-collaboration-agreement/</loc>
		<lastmod>2008-10-18T19:23:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 133: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/calypso%c2%ae-medical-and-impac-medical-systems-to-develop-motion-management-solutions/</loc>
		<lastmod>2008-10-18T19:22:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 124: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/isis-and-excaliard-collaborate-to-develop-antisense-drugs-for-local-treatment-of-fibrotic-diseases/</loc>
		<lastmod>2008-10-18T19:22:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 32: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/cleveland-office-opening/</loc>
		<lastmod>2008-10-18T19:21:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 118: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-announces-288-million-financing-and-initiation-of-pivotal-clinical-trial/</loc>
		<lastmod>2008-10-18T19:21:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 107: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/tissuelink-medical-changes-name-to-salient-surgical-technologies/</loc>
		<lastmod>2008-10-18T19:20:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 90: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/tryton-medical-inc-closes-14-million-financing/</loc>
		<lastmod>2008-10-18T19:20:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 37: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/rivervest-venture-partners%c2%ae-a-st-louis-based-venture-capital-firm-focusing-on-life-sciences-closes-on-fund-ii-names-john-p-mckearn-phd-venture-partner/</loc>
		<lastmod>2008-10-18T19:19:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1045: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/j-greg-davis-appointed-president-chief-executive/</loc>
		<lastmod>2008-10-18T19:19:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1041: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/fda-clears-calyso%c2%ae-medicals-gps-for-the-body%c2%ae/</loc>
		<lastmod>2008-10-18T19:18:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1082: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/macrogenics-appoints-new-chief-commercial-officer-and-chief-financial-officer/</loc>
		<lastmod>2008-10-18T19:18:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1065: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/fda-clears-new-applicators-for-endometrial-cancer-treatment-with-xofts-axxent%c2%ae-electronic-brachytherapy-system/</loc>
		<lastmod>2008-10-18T19:17:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1078: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/accumetrics-announces-the-launch-and-first-patient-enrolled-into-the-gravitas-trial/</loc>
		<lastmod>2008-10-18T19:17:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1051: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/calypso%c2%ae-medical%e2%80%99s-eric-r-meier-named-ernst-young-entrepreneur-of-the-year%c2%ae-2008-pacific-northwest-winner-in-the-health-care-life-sciences-category/</loc>
		<lastmod>2008-10-18T19:15:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1073: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/first-breast-cancer-patient-receives-treatment-in-national-electronic-brachytherapy-registry-launched-by-three-physician-societies/</loc>
		<lastmod>2008-10-18T19:15:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1085: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/macrogenics-acquires-raven-biotechnologies/</loc>
		<lastmod>2008-10-18T19:14:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1057: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/centerre-expands-development-team/</loc>
		<lastmod>2008-10-18T19:14:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1178: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/calypso%c2%ae-medical-technologies-reports-advancements-in-radiation-treatment-for-cancer-patients/</loc>
		<lastmod>2008-10-18T19:13:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1060: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/xoft-secures-25-million-in-additional-funding-for-award-winning-electronic-brachytherapy-technology/</loc>
		<lastmod>2008-10-18T19:13:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1172: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/calypso-medical-and-siemens-announce-innovative-product-development-collaboration-agreement/</loc>
		<lastmod>2008-10-18T19:12:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1182: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/macrogenics-raises-25m-in-series-d-2-financing/</loc>
		<lastmod>2008-10-18T19:12:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1258: Comments: 0 of 0 = 0 points -->	<url>
		<loc>http://www.rivervest.com/excaliard-pharmaceuticals-appoints-lincoln-krochmal-md-president-chief-executive-officer-and-jeffrey-jensen-head-of-clinical-operations/</loc>
		<lastmod>2008-10-18T19:12:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/contact-us-2/</loc>
		<lastmod>2008-10-18T18:47:44+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/home/home-page-case-study-2/</loc>
		<lastmod>2008-10-18T18:21:55+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/mobile/</loc>
		<lastmod>2008-10-18T18:18:52+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.rivervest.com/news/</loc>
		<lastmod>2008-10-01T03:06:06+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: End Postings --><!-- Debug: Start Custom Pages --><!-- Debug: End Custom Pages --><!-- Debug: Start additional URLs --><!-- Debug: End additional URLs --></urlset>
